Page 45 - Read Online

Nasr et al. Metab Target Organ Damage 2023;3:19 https://dx.doi.org/10.20517/mtod.2023.20 Page 11 of 17

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact
of ethnicity. Hepatology 2004;40:1387-95. DOI
2. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the
United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524-530.e1; quiz e60. DOI
3. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686-90. DOI
4. Rinella ME, Lazarus JV, Ratziu V, et al. NAFLD Nomenclature consensus group. A multi-society Delphi consensus statement on
new fatty liver disease nomenclature. Available from: https://www.journal-of-hepatology.eu/article/S0168-8278(23)00418-X/fulltext
[Last accessed on 23 Oct 2023].
5. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
Available from: https://www.sciencedirect.com/science/article/pii/S1665268123002375 [Last accessed on 23 Oct 2023].
6. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease
(NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023;77:1335-47. DOI PubMed PMC
7. Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore
identical. J Hepatol ;2023:S0168-8278(23)05080. DOI
8. Rinella ME, Lazarus JV, Ratziu V, et al. NAFLD Nomenclature consensus group. A multi-society Delphi consensus statement on
new fatty liver disease nomenclature. Available from:https://journals.lww.com/hep/fulltext/9900/a_multi_society_delphi_consensus_
statement_on_new.488.aspx [Last accessed on 23 Oct 2023].
9. Sherlock S. The Clinician Looks at Fatty Liver.
10. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty
liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology
2011;53:810-20. DOI PubMed PMC
11. Kleiner DE, Brunt EM, Van Natta M, et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a
histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21. DOI
12. Nasr P, Forsgren MF, Ignatova S, et al. Using a 3% proton density fat fraction as a cut-off value increases sensitivity of detection of
hepatic steatosis, based on results from histopathology analysis. Gastro 2017;153:53-55.e7. DOI
13. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence
of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-8. DOI
14. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for
assessing steatosis. J Hepatol 2017;66:1022-30. DOI PubMed
15. Saad L. Majority in US drink alcohol, averaging four drinks a week. Available from: https://news.gallup.com/poll/156770/majority-
drink-alcohol-averaging-four-drinks-week.aspx [Last accessed on 22 Oct 2023].
16. Trolldal B, Leifman H. Alkoholkonsumtionen i Sverige 2017. CAN Rapport 175. Hämtad från Centralförbundet för alkohol-och
narkotikaupplysnings webbplats: Available from: https://www.can.se/app/uploads/2020/01/can-rapport-175-alkoholkonsumtionen-i-
sverige-2017.pdf [Last accessed on 22 Oct 2023].
17. Eurobarometer S. EU citizens’ attitudes towards alcohol. Available from: https://data.europa.eu/data/datasets/s798_72_3_
ebs331?locale=en[Last accessed on 23 Oct 2023].
18. Zhou Z, Wang L, Song Z, Lambert JC, McClain CJ, Kang YJ. A critical involvement of oxidative stress in acute alcohol-induced
hepatic TNF-alpha production. Am J Pathol 2003;163:1137-46. DOI PubMed PMC
19. Chen J, Martin-Mateos R, Li J, et al. Multiparametric magnetic resonance imaging/magnetic resonance elastography assesses
progression and regression of steatosis, inflammation, and fibrosis in alcohol-associated liver disease. Alcohol Clin Exp Res
2021;45:2103-17. DOI PubMed PMC
20. Belfrage P, Berg B, Cronholm T, et al. Prolonged administration of ethanol to young, healthy volunteers: effects on biochemical,
morphological and neurophysiological parameters. Acta Med Scand Suppl ;1973:552:1-44. PubMed
21. Kechagias S, Zanjani S, Gjellan S, et al. Effects of moderate red wine consumption on liver fat and blood lipids: a prospective
randomized study. Ann Med 2011;43:545-54. DOI
22. Rasmussen DN, Thiele M, Johansen S, et al; GALAXY; MicrobLiver consortia. Prognostic performance of 7 biomarkers compared
to liver biopsy in early alcohol-related liver disease. J Hepatol 2021;75:1017-25. DOI PubMed PMC
23. Thiele M, Rausch V, Fluhr G, et al. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of
alcohol detoxification. J Hepatol 2018;68:1025-32. DOI
24. Donohue TM Jr. Alcohol-induced steatosis in liver cells. World J Gastroenterol 2007;13:4974-8. DOI PubMed PMC